Grown Rogue International Valuation

Is GRIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GRIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GRIN?

Key metric: As GRIN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GRIN. This is calculated by dividing GRIN's market cap by their current earnings.
What is GRIN's PE Ratio?
PE Ratio	37.6x
Earnings	US$3.86m
Market Cap	US$145.21m

GRIN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.8x
Enterprise Value/EBITDA	29.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does GRIN's PE Ratio compare to its peers?

The above table shows the PE ratio for GRIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	26x
RX BioSyent	19.5x	n/a	CA$138.9m
HASH Simply Solventless Concentrates	46.5x	n/a	CA$53.3m
CPH Cipher Pharmaceuticals	16.2x	10.0%	CA$364.4m
MDP Medexus Pharmaceuticals	21.9x	50.2%	CA$71.5m
GRIN Grown Rogue International	37.6x	n/a	CA$206.7m

Price-To-Earnings vs Peers: GRIN is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the peer average (26x).

Price to Earnings Ratio vs Industry

How does GRIN's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

14 Companies	Price / Earnings	Estimated Growth	Market Cap

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: GRIN is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the North American Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is GRIN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GRIN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	37.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GRIN's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.